Masashi Miyamoto, Ph.D.
Representative Director President and Chief Executive Officer

“At Kyowa Kirin we value all our colleagues regardless of diverse backgrounds, stand firmly against any discrimination based on sexual orientation or gender identity, and are committed to creating an inclusive workplace where everyone has an equal opportunity to succeed and grow.”

Kyowa Kirin relies on a diverse team of experts who are passionate about innovation to achieve our mission and 2030 goal of delivering new medicines with life-changing value that brings smiles to patients. Last year we officially defined a DE&I (Diversity, Equity and Inclusion) Statement for the Kyowa Kirin Group: We celebrate the power of diversity of thought and values while at the same time acknowledge the need to confront our own biases in order to break down inequities in the workplace. Our journey toward our Vision will depend upon every step we take to create an environment where everyone feels safe and empowered to thrive as their authentic self.

June is the “Pride Month” which is marked to celebrate the rights of LGBTQ+ communities. Initially triggered by the Stonewall Uprising in June 1969 which involved LGBTQ+ members fighting for their civil rights in New York City, today a variety of events and pride marches are held around the world to honor the Stonewall Uprising. In Japan also, “Tokyo Rainbow Pride” is held annually during Golden Week (a holiday week in late April-early May) which started in 2012 and has grown to prominence as a symbolic event of the LGBTQ+ movement. In full support of the cause of these events, at Kyowa Kirin we value all our colleagues regardless of diverse backgrounds, stand firmly against any discrimination based on sexual orientation or gender identity, and are committed to creating an inclusive workplace where everyone has an equal opportunity to succeed and grow.

Being LGBTQ+ may easily go unnoticed unless the person chooses to let others around them know. Without one’s awareness of DE&I, we may unknowingly end up with certain groups of individuals feeling vulnerable and suppressing their true identity in order to fit in. It takes conscious efforts to practice DE&I to create a workplace in which members feel safe to reveal their true selves to each other which will in turn generate the power of “diverse team of experts with shared passion for innovation" as stated in our Vision. Sharing this message with all Kyowa Kirin employees, I encourage them to take an interest and show support for Pride-related events and initiatives.

More Kyowa Kirin "People & Culture" Stories

Providing high-quality pharmaceuticals to patients around the world

Sustainability | September 22, 2022

Striving to create life-changing “Only-one value” that brings smiles to patients

Innovation | July 25, 2022

Kyowa Kirin International: It's Time to Shine A Light on XLH

Patients | June 27, 2022

Kyowa Kirin CEO Miyamoto’s Message on Pride Month

People & Culture | June 9, 2022

Pharmacovigilance Activities (Part II): Adopting a Momotaro Mindset to Overcome Challenges - Global PV Function Member Dialogue -

Patients | March 10, 2022Open in new window

Pharmacovigilance Activities (Part I): Bringing Smiles to Patients by Supporting Medicinal Product Safety Monitoring Activities on a Global Scale

Patients | February 22, 2022Open in new window

Kyowa Kirin International Celebrates the UN’s International Day of Persons with Disabilities in EMEA

People & Culture | January 20, 2022

Kyowa Kirin International: Around the world challenge

People & Culture | December 17, 2021Open in new window

Kyowa Kirin North America: Honoring The Caregiver, Everyday Heroes, During National Family Caregivers Month

Patients | November 19, 2021

Kyowa Kirin's Effort to Realize a Sustainable Society

Sustainability | October 11, 2021

Our Financial Strategy for Creating Life-changing Value

Growth | September 9, 2021

Changes in society caused by COVID-19 and the impact on Kyowa Kirin

Growth | August 19, 2021

Bio Adventure Hands-On Experience Sessions: Become a drug discovery researcher During Your Summer Break

Sustainability | July 27, 2021Open in new window

AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS

News Release | June 1, 2021

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting

News Release | May 20, 2021

White Paper on the unrecognized burden of XLH in adults in Europe

Patients | July 13, 2020

Return to Stories